Research Analysts Set Expectations for Balchem Q3 Earnings

Balchem Co. (NASDAQ:BCPC - Free Report) - Equities researchers at Sidoti Csr lifted their Q3 2025 earnings estimates for Balchem in a report released on Monday, April 28th. Sidoti Csr analyst D. Harriman now expects that the basic materials company will post earnings per share of $1.36 for the quarter, up from their previous forecast of $1.30. The consensus estimate for Balchem's current full-year earnings is $4.64 per share. Sidoti Csr also issued estimates for Balchem's Q4 2025 earnings at $1.33 EPS, FY2025 earnings at $5.15 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.39 EPS, Q4 2026 earnings at $1.35 EPS and FY2026 earnings at $5.45 EPS.

Balchem (NASDAQ:BCPC - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 EPS for the quarter, missing analysts' consensus estimates of $1.25 by ($0.03). Balchem had a net margin of 13.47% and a return on equity of 11.37%. The business had revenue of $250.52 million during the quarter, compared to analysts' expectations of $245.70 million. During the same quarter last year, the business posted $1.03 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year.

Other analysts have also issued research reports about the stock. HC Wainwright set a $180.00 price objective on shares of Balchem and gave the stock a "buy" rating in a research note on Monday, April 28th. StockNews.com downgraded Balchem from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Finally, Sidoti upgraded Balchem to a "hold" rating in a research report on Tuesday, February 25th.

Balchem Stock Performance

Shares of Balchem stock traded up $4.99 on Tuesday, reaching $161.87. 134,973 shares of the stock were exchanged, compared to its average volume of 134,262. Balchem has a twelve month low of $145.70 and a twelve month high of $186.03. The business has a 50 day moving average price of $163.28 and a two-hundred day moving average price of $166.61. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $5.28 billion, a price-to-earnings ratio of 41.19, a PEG ratio of 4.41 and a beta of 0.93.

Hedge Funds Weigh In On Balchem

Hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC lifted its position in shares of Balchem by 8.2% during the 4th quarter. Quadrant Capital Group LLC now owns 989 shares of the basic materials company's stock valued at $161,000 after buying an additional 75 shares in the last quarter. Covestor Ltd raised its holdings in shares of Balchem by 93.8% during the fourth quarter. Covestor Ltd now owns 157 shares of the basic materials company's stock valued at $26,000 after acquiring an additional 76 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Balchem by 0.8% in the fourth quarter. Arizona State Retirement System now owns 9,413 shares of the basic materials company's stock valued at $1,534,000 after acquiring an additional 77 shares in the last quarter. Vident Advisory LLC boosted its stake in shares of Balchem by 6.0% in the fourth quarter. Vident Advisory LLC now owns 1,421 shares of the basic materials company's stock worth $232,000 after acquiring an additional 80 shares during the last quarter. Finally, Heritage Family Offices LLP increased its position in shares of Balchem by 5.9% during the first quarter. Heritage Family Offices LLP now owns 1,504 shares of the basic materials company's stock worth $250,000 after purchasing an additional 84 shares in the last quarter. Hedge funds and other institutional investors own 87.91% of the company's stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.